13F Portfolios

Fairmount Funds Management LLC: DAMORA THERAPEUTICS INC (DMRA): Quarterly 13F Position History

As of Q2 2026, Fairmount Funds Management LLC reported 8,713,000 shares of DAMORA THERAPEUTICS INC (DMRA), worth $226.6M and representing 15.0% of its 13F equity book. The position first appeared in Q1 2026 and has been disclosed across 2 13F-HR filings in Pactolio's tracked window.

Recent initiation: Fairmount Funds Management LLC first reported DMRA on the Q1 2026 filing, so fewer than three quarters of history are available.

Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 2 quarter s

Quarter Shares QoQ Share Change Share Change (%) Market Value Weight Implied Price
Q2 2026 8,713,000 0 $226.6M 15.0% $26.0
Q1 2026 8,713,000 $225.7M 16.3% $25.9

Methodology & FAQ

How This Position History Is Sourced

Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares, a quarter-end mark rather than the manager's cost basis. See the full methodology document for the normalization rules.

When did Fairmount Funds Management LLC first disclose a DMRA position in 13F-HR filings?

Fairmount Funds Management LLC first reported DAMORA THERAPEUTICS INC (DMRA) on its 13F-HR filing for the period ending 2026-03-31 (Q1 2026). The position has appeared on 2 reported quarters within Pactolio's tracked window.

What was Fairmount Funds Management LLC's most recent quarter-over-quarter share-count change in DMRA?

Fairmount Funds Management LLC held the same 8,713,000 shares of DMRA between Q1 2026 and Q2 2026, so the reported share count was unchanged quarter-over-quarter.

Does the implied price-per-share represent Fairmount Funds Management LLC's cost basis in DMRA?

No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.